CA2420576A1 - Immunoregulatory compounds, derivatives thereof and their use - Google Patents

Immunoregulatory compounds, derivatives thereof and their use Download PDF

Info

Publication number
CA2420576A1
CA2420576A1 CA002420576A CA2420576A CA2420576A1 CA 2420576 A1 CA2420576 A1 CA 2420576A1 CA 002420576 A CA002420576 A CA 002420576A CA 2420576 A CA2420576 A CA 2420576A CA 2420576 A1 CA2420576 A1 CA 2420576A1
Authority
CA
Canada
Prior art keywords
alkyl
hydrogen
compounds
group
derivatives
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Granted
Application number
CA002420576A
Other languages
French (fr)
Other versions
CA2420576C (en
Inventor
Nnochiri N. Ekwuribe
Jennifer Riggs-Sauthier
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Biocon Ltd
Original Assignee
Nobex Corporation
Nnochiri N. Ekwuribe
Jennifer Riggs-Sauthier
Biocon Limited
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Nobex Corporation, Nnochiri N. Ekwuribe, Jennifer Riggs-Sauthier, Biocon Limited filed Critical Nobex Corporation
Priority to CA2495537A priority Critical patent/CA2495537C/en
Publication of CA2420576A1 publication Critical patent/CA2420576A1/en
Application granted granted Critical
Publication of CA2420576C publication Critical patent/CA2420576C/en
Anticipated expiration legal-status Critical
Expired - Lifetime legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
    • A61K31/19—Carboxylic acids, e.g. valproic acid
    • A61K31/195—Carboxylic acids, e.g. valproic acid having an amino group
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
    • A61K31/19—Carboxylic acids, e.g. valproic acid
    • A61K31/195—Carboxylic acids, e.g. valproic acid having an amino group
    • A61K31/196—Carboxylic acids, e.g. valproic acid having an amino group the amino group being directly attached to a ring, e.g. anthranilic acid, mefenamic acid, diclofenac, chlorambucil
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/21—Esters, e.g. nitroglycerine, selenocyanates
    • A61K31/215—Esters, e.g. nitroglycerine, selenocyanates of carboxylic acids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/21—Esters, e.g. nitroglycerine, selenocyanates
    • A61K31/215—Esters, e.g. nitroglycerine, selenocyanates of carboxylic acids
    • A61K31/235—Esters, e.g. nitroglycerine, selenocyanates of carboxylic acids having an aromatic ring attached to a carboxyl group
    • A61K31/24—Esters, e.g. nitroglycerine, selenocyanates of carboxylic acids having an aromatic ring attached to a carboxyl group having an amino or nitro group
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C229/00—Compounds containing amino and carboxyl groups bound to the same carbon skeleton
    • C07C229/40—Compounds containing amino and carboxyl groups bound to the same carbon skeleton having amino groups bound to carbon atoms of at least one six-membered aromatic ring and carboxyl groups bound to acyclic carbon atoms of the same carbon skeleton
    • C07C229/42—Compounds containing amino and carboxyl groups bound to the same carbon skeleton having amino groups bound to carbon atoms of at least one six-membered aromatic ring and carboxyl groups bound to acyclic carbon atoms of the same carbon skeleton with carboxyl groups linked to the six-membered aromatic ring, or to the condensed ring system containing that ring, by saturated carbon chains
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C245/00—Compounds containing chains of at least two nitrogen atoms with at least one nitrogen-to-nitrogen multiple bond
    • C07C245/02—Azo compounds, i.e. compounds having the free valencies of —N=N— groups attached to different atoms, e.g. diazohydroxides
    • C07C245/06—Azo compounds, i.e. compounds having the free valencies of —N=N— groups attached to different atoms, e.g. diazohydroxides with nitrogen atoms of azo groups bound to carbon atoms of six-membered aromatic rings
    • C07C245/08—Azo compounds, i.e. compounds having the free valencies of —N=N— groups attached to different atoms, e.g. diazohydroxides with nitrogen atoms of azo groups bound to carbon atoms of six-membered aromatic rings with the two nitrogen atoms of azo groups bound to carbon atoms of six-membered aromatic rings, e.g. azobenzene
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
    • Y02A—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
    • Y02A50/00—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE in human health protection, e.g. against extreme weather
    • Y02A50/30—Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change

Abstract

Compounds are disclosed having the structure of Formula (I), where R1, R3, and R4 are independently hydrogen or C1 to C4 alkyl, and R2 is (II), where R5 is selected from the group consisting of hydrogen and C1 to C4 alkyl, or (III), where R6, R7 and R8 are independently hydrogen or C1 to C4 alkyl; or the esters or pharmacologically acceptable salts thereof. Such compounds may be utilized for the prophylaxis or treatment of various diseases, particularly inflammatory conditions of the GI tract. Methods of treating inflammatory conditions of the GI tract such as inflammatory bowel disease using compounds having the following formula are also disclosed (IV), where R9, R10 and R11 are independently selected from the group consisting of hydrogen and C1 to C4 alkyl, and R12 is selected from the group consisting of hydrogen and -C(O)R13, where R13 is a C1 to C6 alkyl or an aryl group.
CA002420576A 2000-08-29 2001-08-28 Immunoregulatory compounds, derivatives thereof and their use Expired - Lifetime CA2420576C (en)

Priority Applications (1)

Application Number Priority Date Filing Date Title
CA2495537A CA2495537C (en) 2000-08-29 2001-08-28 Immunoregulatory compounds and derivatives and methods of treating diseases therewith

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US22868300P 2000-08-29 2000-08-29
US60/228,683 2000-08-29
PCT/US2001/026697 WO2002018324A2 (en) 2000-08-29 2001-08-28 Immunoregulatory compounds, derivatives thereof and their use

Related Child Applications (1)

Application Number Title Priority Date Filing Date
CA2495537A Division CA2495537C (en) 2000-08-29 2001-08-28 Immunoregulatory compounds and derivatives and methods of treating diseases therewith

Publications (2)

Publication Number Publication Date
CA2420576A1 true CA2420576A1 (en) 2002-03-07
CA2420576C CA2420576C (en) 2005-06-14

Family

ID=22858180

Family Applications (2)

Application Number Title Priority Date Filing Date
CA002420576A Expired - Lifetime CA2420576C (en) 2000-08-29 2001-08-28 Immunoregulatory compounds, derivatives thereof and their use
CA2495537A Expired - Lifetime CA2495537C (en) 2000-08-29 2001-08-28 Immunoregulatory compounds and derivatives and methods of treating diseases therewith

Family Applications After (1)

Application Number Title Priority Date Filing Date
CA2495537A Expired - Lifetime CA2495537C (en) 2000-08-29 2001-08-28 Immunoregulatory compounds and derivatives and methods of treating diseases therewith

Country Status (16)

Country Link
US (5) US6583128B2 (en)
EP (2) EP1642885B1 (en)
JP (1) JP4163946B2 (en)
AT (2) ATE448194T1 (en)
AU (3) AU2001285311B2 (en)
CA (2) CA2420576C (en)
CY (1) CY1110593T1 (en)
DE (2) DE60140491D1 (en)
DK (2) DK1313697T3 (en)
ES (2) ES2333337T3 (en)
HK (2) HK1054221A1 (en)
IL (3) IL154536A0 (en)
MX (1) MXPA03001787A (en)
PT (1) PT1642885E (en)
TW (1) TWI249519B (en)
WO (1) WO2002018324A2 (en)

Families Citing this family (30)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP1642885B1 (en) 2000-08-29 2009-11-11 Biocon Limited Use of a pharmaceutical composition containing a para-aminophenyl acetic acid derivative for treating inflammatory conditions of the gastrointestinal tract
US8048924B2 (en) * 2001-08-29 2011-11-01 Biocon Limited Methods and compositions employing 4-aminophenylacetic acid compounds
CA2504287A1 (en) * 2002-11-26 2004-06-10 Nobex Corporation Natriuretic compounds, conjugates, and uses thereof
US7648962B2 (en) * 2002-11-26 2010-01-19 Biocon Limited Natriuretic compounds, conjugates, and uses thereof
US20060182692A1 (en) 2003-12-16 2006-08-17 Fishburn C S Chemically modified small molecules
KR101168620B1 (en) * 2003-12-16 2012-08-03 넥타르 테라퓨틱스 Pegylated small molecules
US8198328B2 (en) * 2004-01-21 2012-06-12 New York University Treatment of cancer using benzoic acid derivatives
JP2007520495A (en) 2004-02-06 2007-07-26 ボロディー トーマス ユリウス Use of aminosalicylic acid in diarrhea-type irritable bowel syndrome
ES2687039T3 (en) * 2004-03-23 2018-10-23 Biocon Limited Methods and compositions employing 4-aminophenylacetic acid compounds
CN1988897B (en) * 2004-05-28 2011-06-29 萨利克斯药物有限公司 Use of balsalazide in preparing medicine for radiation induced enteritis
US20080306029A1 (en) * 2004-05-28 2008-12-11 Salix Pharmaceuticals, Inc. Prevention, Treatment, and Amelioration of Radiation Induced Enteritis
US7932366B2 (en) * 2004-07-07 2011-04-26 Biocon Limited Synthesis of azo bonded immunoregulatory compounds
WO2006076471A2 (en) * 2005-01-12 2006-07-20 Nobex Corporation Bnp conjugates and methods of use
EP1688413A1 (en) * 2005-02-03 2006-08-09 Hikma Pharmaceuticals Co. Ltd. Benzoxazole derivatives for the prophylaxis and treatment of inflammatory bowel diseases
ITRM20050389A1 (en) 2005-07-22 2007-01-23 Giuliani Spa COMPOUNDS AND THEIR SPECIFIC SALTS FOR PPAR RECEPTORS AND RECEPTORS FOR EGF AND THEIR USE IN MEDICAL FIELDS.
ITRM20050390A1 (en) 2005-07-22 2007-01-23 Giuliani Spa COMPOUNDS AND THEIR SPECIFIC SALTS FOR PPAR RECEPTORS AND RECEPTORS FOR EGF AND THEIR USE IN MEDICAL FIELDS.
US8921344B2 (en) * 2006-11-03 2014-12-30 Salix Pharmaceuticals, Inc. Formulations and uses of 2-hydroxy-5-phenylazobenzoic acid derivatives
US7452872B2 (en) * 2005-08-24 2008-11-18 Salix Pharmaceuticals, Inc. Formulations and uses of 2-hydroxy-5-phenylazobenzoic acid derivatives
CN102670626A (en) * 2005-08-24 2012-09-19 萨利克斯药品公司 Balsalazide formulations and manufacture and use thereof
IE20070129A1 (en) * 2007-02-28 2008-12-24 Giuliani Int Ltd Ppar-gamma agonists stimulate enteric defensin expression
US7541384B2 (en) 2007-06-08 2009-06-02 Axcan Pharma Inc. Mesalamine suppository
US8436051B2 (en) * 2007-06-08 2013-05-07 Aptalis Pharma Canada Inc. Mesalamine suppository
US8217083B2 (en) * 2007-06-08 2012-07-10 Aptalis Pharma Canada Inc. Mesalamine suppository
US20090082314A1 (en) * 2007-06-29 2009-03-26 The Provost Fellows And Scholars Of The College Of The Targeting Prodrugs for the Treatment of Gastrointestinal Diseases
ITMI20072429A1 (en) * 2007-12-24 2009-06-25 Giuliani Int Ltd COMPOUNDS FOR THE SELECTIVE TREATMENT OF THE INTESTINAL IMMUNE-INFLAMMATORY COMPONENT OF THE CELIAC DISEASE
UA107562C2 (en) 2008-12-05 2015-01-26 METHOD OF TREATMENT OF PSORIASIS
JP5645851B2 (en) 2009-02-16 2014-12-24 ノグラ ファーマ リミテッド How to treat hair-related conditions
EA030762B1 (en) 2012-02-09 2018-09-28 Ногра Фарма Лимитед Methods of treating fibrosis
AU2013248397A1 (en) 2012-04-18 2014-10-02 Nogra Pharma Limited Methods of treating lactose intolerance
CN113825739A (en) 2019-02-08 2021-12-21 诺格拉制药有限公司 Process for preparing 3- (4' -aminophenyl) -2-methoxypropionic acid and analogs and intermediates thereof

Family Cites Families (190)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US1157169A (en) * 1914-11-03 1915-10-19 Geigy Ag J R Mordant-dyeing azo dye.
US2270676A (en) 1936-08-20 1942-01-20 Winthrop Chem Co Inc Sulphonic acid amide compound
US2314023A (en) 1939-08-08 1943-03-16 Chem Ind Basel Substantive azo dyestuffs and process of making same
US2336275A (en) 1940-10-10 1943-12-07 Eastman Kodak Co Azo dye compound
US2396019A (en) 1943-02-05 1946-03-05 Claude R Wickard Insecticides
NL301585A (en) 1962-04-23
US3641040A (en) 1968-03-27 1972-02-08 Ciba Geigy Corp Tertiary amino phenyl acetic acids
FR2137211B1 (en) * 1971-05-17 1974-08-02 Bouchara Emile
BE791889A (en) 1971-11-26 1973-05-24 Pharmacia Ab NEW DERIVATIVES OF PYRIDINE
US4348399A (en) 1978-02-02 1982-09-07 American Cyanamid Company Antiatherosclerotic and hypolipidemic 4-(monoalkylamino)phenyl alkane, alkene and alkyne carbinols, aldehydes, carboxylic acids and derivatives
GR68102B (en) 1978-08-08 1981-10-30 Fujisawa Pharmaceutical Co
US4298595A (en) 1978-12-20 1981-11-03 Dynapol Pharmaceutical preparations containing a polymeric agent for releasing 5-aminosalicylic acid or its salts into the gastrointestinal tract
US4189607A (en) * 1979-03-26 1980-02-19 Taisho Pharmaceutical Co., Ltd. Anilionotropone derivatives
JPS57500432A (en) 1980-03-20 1982-03-11
US4960765A (en) 1980-03-20 1990-10-02 Farmaceutisk Laboratorium Ferring A/S Pharmaceutical composition and method for the treatment of colitis ulcerosa and Crohn's disease by oral administration
SE8002321L (en) * 1980-03-26 1981-09-27 Pharmacia Ab SETS AND INTERMEDIATES FOR PREPARING BENZOIC ACID DERIVATIVES
SE8002322L (en) 1980-03-26 1981-09-27 Pharmacia Ab Means for the treatment of inflammatory bowel diseases
DE3027013A1 (en) 1980-07-17 1982-02-18 Henning Berlin Gmbh Chemie- Und Pharmawerk, 1000 Berlin AGENTS FOR THE TREATMENT OF COLITIS ULCEROSA, ENTERITIS REGIONALIS CROHN (MORBUS CROHN), CHRONICALLY SPECIFIC COLITIS AND DIVERTICULITIS, AND USE OF SALICYLAZOBOZOIC ACID, FOR THE PRODUCTION OF SUCH A MEDIUM
US4412992A (en) * 1980-07-21 1983-11-01 Biorex Laboratories Limited 2-Hydroxy-5-phenylazobenzoic acid derivatives and method of treating ulcerative colitis therewith
DE3047106A1 (en) * 1980-12-13 1982-07-29 Henkel Kgaa TOPICAL COSMETIC PREPARATIONS FOR TREATING STRONG OILY HAIR AND SEBORRHEA SKIN
US4374932A (en) 1981-06-08 1983-02-22 G. D. Searle & Co. 5-ASA Drug delivery system
ZA825384B (en) 1981-07-31 1983-05-25 Tillott J B Ltd Orally administrable pharmaceutical compositions
DE3151196A1 (en) 1981-12-23 1983-06-30 Kurt Heinz Prof. Dr. 7800 Freiburg Bauer METHOD FOR PRODUCING EASILY SOLUBLE 5-AMINOSALICYL ACID MEDICAL PREPARATIONS
FR2520233A1 (en) * 1982-01-28 1983-07-29 Oreal COMPOSITION OF ANTHRALIN OR ONE OF ITS DERIVATIVES IN AN AROMATIC ESTER AND ITS USE IN THE TREATMENT OF SKIN DISEASES
JPS58194814A (en) 1982-05-11 1983-11-12 Nippon Shinyaku Co Ltd Drug having immunoregulating activity
JPS59196839A (en) 1983-04-21 1984-11-08 Sankyo Co Ltd Phenylacetic acid derivative
SE8303399D0 (en) 1983-06-15 1983-06-15 Pharmacia Ab AZO-BIS-SALICYL ACID AND SALT THEREOF, THEIR PHARMACEUTICAL PREPARATION AND PREPARATION OF THE ACID
DE3323702A1 (en) 1983-07-01 1985-01-10 Henning Berlin Gmbh Chemie- Und Pharmawerk, 1000 Berlin 5-AMINOSALICYL ACID-O-SULFATES OF PHYSIOLOGICALLY POSSIBLE BASES, METHOD FOR THE PRODUCTION THEREOF AND MEDICINAL PRODUCTS CONTAINING THEM
US4539198A (en) 1983-07-07 1985-09-03 Rowell Laboratories, Inc. Solid pharmaceutical formulations for slow, zero order release via controlled surface erosion: expanded range
USRE33239E (en) 1983-09-06 1990-06-26 Farmaceutisk Laboratorium Ferring A/S Packaged stable enema solution or suspension containing 5-aminosalicyclic acid
US4664256A (en) 1983-09-06 1987-05-12 Farmaceutisk Laboratorium Ferring A/S Packaged stable enema solution or suspension containing 5-aminosalicyclic acid
US4657900A (en) 1983-09-27 1987-04-14 Rowell Laboratories Pharmaceutical article of manufacture comprising a bisulfite stabilized aqueous solution of 5-aminosalicylic acid and method
US4628083A (en) * 1983-10-17 1986-12-09 Pharmacia Ab 2-hydroxy-5-(arylazo)-benzene alkanoic acids
SE457505B (en) 1984-01-10 1989-01-09 Lejus Medical Ab LAMINATED ORAL PHARMACEUTICAL COMPOSITION AND PROCEDURES FOR ITS PREPARATION
US5137916A (en) * 1985-11-14 1992-08-11 The Rockefeller University Advanced glycation inhibitors containing amino-benzoic acids and derivatives, and methods of use
US5272176A (en) * 1984-03-19 1993-12-21 The Rockefeller University Advanced glycation inhibitors containing amino-benzoic acids and derivatives, and methods of use
US5514676A (en) 1984-03-19 1996-05-07 The Rockefeller University Amino-benzoic acids and derivatives, and methods of use
US5476849A (en) 1984-03-19 1995-12-19 The Rockefeller University Methods for glycosylation inhibition using amino-benzoic acids and derivatives
US4663308A (en) 1984-07-18 1987-05-05 Medical College Of Ohio Method of use of polymers containing cross-linked azo bonds for releasing therapeutic agents into the lower gastrointestinal tract
DK153412C (en) 1984-11-22 1988-12-19 Ferring A S PROCEDURE FOR THE PREPARATION OF P-AMINOPHENOLS BY ELECTROLYSE
SE8405924L (en) 1984-11-23 1986-05-24 Pharmacia Ab NEW AZO ASSOCIATIONS
US4737240A (en) * 1985-05-02 1988-04-12 Ciba-Geigy Corporation Trisazo black dyes from 2-(4'-aminophenylazo)-7-amino-1-naphthol-3-sulfonic acid
ES8606254A1 (en) * 1985-05-31 1986-04-01 Lasa Lab Prepn. of para -amino-benzoic acid derivs.
JPS62240620A (en) 1986-04-10 1987-10-21 Hidekazu Masuhara Sedative for toothache containing n-methacryloyl-aminosalicylic acid
IN169307B (en) * 1986-05-03 1991-09-28 Hoechst Ag
SE462095B (en) 1986-07-07 1990-05-07 Nobel Kemi Ab SAID TO MAKE 5-AMINOSALICYLIC ACID
DE3627461A1 (en) * 1986-08-13 1988-02-25 Basf Ag DYE MIXTURES
US4999347A (en) * 1986-08-28 1991-03-12 Sorenson John R J Analgesic method
US4873321A (en) * 1986-10-17 1989-10-10 Sumitomo Chemical Company, Limited Monazo compounds having a triozinyl bridging group and two vinylsulfone type fiber reactive groups
US5026560A (en) 1987-01-29 1991-06-25 Takeda Chemical Industries, Ltd. Spherical granules having core and their production
DE3889365D1 (en) * 1987-03-13 1994-06-09 Moeller Willi Ag Adducts of keto compounds and anions of oxa acids, processes for their preparation, their use and azoketo compounds.
AU1388388A (en) 1987-04-01 1988-10-06 Dak-Laboratoriet A/S Benzoic acid derivatives and use thereof
US5274002A (en) 1987-04-14 1993-12-28 Warner-Lambert Company Trisubstituted phenyl analogs having activity for congestive heart failure
GB8709248D0 (en) 1987-04-16 1987-05-20 Wyeth John & Brother Ltd Azo compounds
US4849416A (en) 1988-07-25 1989-07-18 Rorer Pharmaceutical Corporation Treatment of conditions requiring enhanced oxygen availability to mammalian tissues
US5484605A (en) 1988-11-25 1996-01-16 Henning Berlin Gmbh Chemie-Und Pharmawerk Agent for treating chronically inflammatory intestinal diseases
EP0390499B2 (en) * 1989-03-30 2000-02-16 Ngk Insulators, Ltd. Process for producing bismuth-based superconducting material
GB8909559D0 (en) 1989-04-26 1989-06-14 Smith Kline French Lab Pharmaceutical compositions
US5010069A (en) 1989-05-15 1991-04-23 Marion Laboratories, Inc. Stable liquid form of 5-aminosalicylic acid
US5378470A (en) 1989-07-25 1995-01-03 Henning Berlin Gmbh Rectally administered pharmaceutical preparation
IT1246383B (en) 1990-04-17 1994-11-18 Eurand Int METHOD FOR MASKING THE TASTE OF DRUGS
US5298497A (en) * 1990-05-15 1994-03-29 E. R. Squibb & Sons, Inc. Method for preventing onset of hypertension employing a cholesterol lowering drug
US5214191A (en) * 1990-05-22 1993-05-25 Cortech, Inc. Oxidant sensitive and insensitive aromatic esters as inhibitors of human neutrophil elastase
US5637618A (en) 1990-06-01 1997-06-10 Bioresearch, Inc. Specific eatable taste modifiers
US5629020A (en) 1994-04-22 1997-05-13 Emisphere Technologies, Inc. Modified amino acids for drug delivery
US5244922A (en) * 1990-09-04 1993-09-14 Burzynski Stanislaw R Methods for treating viral infections
US5254587A (en) 1990-09-04 1993-10-19 Burzynski Stanislaw R Methods for treating AIDS
US5519014A (en) * 1990-10-22 1996-05-21 Borody; Thomas J. Treatment of non-inflammatory and non-infectious bowel disorders
GB9311281D0 (en) * 1993-06-01 1993-07-21 Rhone Poulenc Rorer Ltd Novel composition of matter
US5663208A (en) 1991-03-01 1997-09-02 Warner-Lambert Company Antifungal wound healing compositions and methods for preparing and using same
US5674912A (en) 1991-03-01 1997-10-07 Warner-Lambert Company Sunscreen-wound healing compositions and methods for preparing and using same
US5602183A (en) 1991-03-01 1997-02-11 Warner-Lambert Company Dermatological wound healing compositions and methods for preparing and using same
US5648380A (en) 1991-03-01 1997-07-15 Warner-Lambert Company Anti-inflammatory wound healing compositions and methods for preparing and using same
US5874479A (en) 1991-03-01 1999-02-23 Warner-Lambert Company Therapeutic permeation enhanced-wound healing compositions and methods for preparing and using same
IT1247884B (en) * 1991-05-03 1995-01-05 Gentili Ist Spa ARYALKYL ESTERS OF THE ACID 4,5 DIHYDROXY-9,10-DIHYDRO-9,10-DIOXY 2-ANTHRACENCARBOXYL THERAPEUTIC ACTION
GB9111426D0 (en) 1991-05-28 1991-07-17 Ici Plc Chemical compounds
US5502078A (en) 1991-05-28 1996-03-26 Zeneca Limited Chemical compounds
CA2110376C (en) 1991-06-07 2003-02-11 Adrianus J. Wittebrood Pharmaceutical enema preparation
US5629012A (en) 1991-06-17 1997-05-13 Farmaceutisk Laboratorium Ferring A/S Process for producing suppositories by compression and suppositories obtained by the process
DE4121849A1 (en) * 1991-07-02 1993-01-14 Rhone Poulenc Rorer Gmbh New 4-(omega-arylalkyl)phenylalkanoic acid derivs. - used as LTB4 inhibitors for treating eczema, psoriasis, acne, arthritis, asthma, allergies or inflammatory bowel disease
US5605930A (en) 1991-10-21 1997-02-25 The United States Of America As Represented By The Department Of Health And Human Services Compositions and methods for treating and preventing pathologies including cancer
US5635532A (en) * 1991-10-21 1997-06-03 The United States Of America As Represented By The Secretary Of The Department Of Health And Human Services Compositions and methods for therapy and prevention of pathologies including cancer, AIDS and anemia
US6037376A (en) 1991-10-21 2000-03-14 The United States Of America As Represented By The Department Of Health And Human Services Methods for therapy of cancer
US5646182A (en) * 1992-06-15 1997-07-08 Burzynski; Stanislaw R. Methods for treating autoimmune diseases
US20050090553A1 (en) * 1992-06-30 2005-04-28 Shapiro Howard K. Compositions and method for treatment of chronic inflammatory diseases
ATE214608T1 (en) * 1992-06-30 2002-04-15 Howard K Shapiro USE OF A COMBINATION CONSISTING OF AN AMINO DERIVATIVE OR AMINE RELATED DERIVATIVE OF BENZOIC ACID AND AN AMINO-POLYSACCHARIDE FOR THE PRODUCTION OF A MEDICATION FOR THE TREATMENT OF INFLAMMATORY DISEASES
US6444221B1 (en) * 1992-06-30 2002-09-03 Howard K. Shapiro Methods of treating chronic inflammatory diseases using carbonyl trapping agents
US5817321A (en) 1992-10-08 1998-10-06 Supratek Pharma, Inc. Biological agent compositions
US6008250A (en) * 1993-05-26 1999-12-28 Bioresearch, Inc. Specific eatable taste modifiers
DK66493D0 (en) 1993-06-08 1993-06-08 Ferring A S PREPARATIONS FOR USE IN TREATMENT OF INFLAMMATORY GAS DISORDERS OR TO IMPROVE IMPROVED HEALTH
US5585391A (en) * 1993-10-08 1996-12-17 Fhj Scientific, Inc. Hydroxyl ions as unique therapeutic agents and compounds that modulate these ions, compositions employing these agents, therapeutic methods for using such agents and processes for preparing them
DE4334678A1 (en) * 1993-10-12 1995-04-13 Basf Ag Method for the detection of labeled mineral oils and new azo dyes
DE4335496A1 (en) * 1993-10-19 1995-04-20 Basf Ag Diphenylamine compounds
FR2713486B1 (en) 1993-12-14 1996-02-09 Scophysa New compositions for foams, in particular rectal foams, and foams thus obtained.
DE4343823A1 (en) * 1993-12-22 1995-06-29 Basf Ag Use of azo dyes for marking hydrocarbons as well as new azo dyes
US5498608A (en) 1994-01-07 1996-03-12 Salix Pharmaceuticals Use of 2-hydroxy-5-phenylazobenzoic acid derivatives as colon cancer chemopreventative and chemotherapeutic agents
GB9400972D0 (en) * 1994-01-19 1994-03-16 Zeneca Ltd Process
US5391575A (en) * 1994-05-04 1995-02-21 Burzynski; Stanislaw R. Method for treating neurofibromatosis
DE69512232T2 (en) * 1994-05-10 2000-02-24 Nicox Sa NITRO CONNECTIONS AND THEIR PREPARATIONS WITH ANTI-FLAMMING, PAINT RELEASING AND ANTITHROMBOTIC EFFECTS
AU698881B2 (en) * 1994-05-11 1998-11-12 Howard K. Shapiro Compositions for treatment of chronic inflammatory diseases
US6245774B1 (en) * 1994-06-21 2001-06-12 Celltech Therapeutics Limited Tri-substituted phenyl or pyridine derivatives
FR2726468B1 (en) * 1994-11-03 1996-12-13 Oreal USE OF SALICYLIC ACID DERIVATIVE AS AN OIL-IN-WATER EMULSION STABILIZER
US5905073A (en) 1995-01-06 1999-05-18 Salix Pharmaceuticals, Inc. Use of 2-hydroxy-5-phenylazobenzoic acid derivatives as colon cancer chemopreventative and chemotherapeutic agents
WO1996030003A1 (en) 1995-03-30 1996-10-03 Werner Kreutz Medicaments for the selective treatment of tumour tissues
US5703073A (en) 1995-04-19 1997-12-30 Nitromed, Inc. Compositions and methods to prevent toxicity induced by nonsteroidal antiinflammatory drugs
JP3964478B2 (en) * 1995-06-30 2007-08-22 エーザイ・アール・アンド・ディー・マネジメント株式会社 Heterocycle-containing carboxylic acid derivative and pharmaceutical containing the same
FR2738150B1 (en) 1995-09-01 1997-10-31 Synthelabo USE OF SULPHASALAZINE AND ITS METABOLITES FOR THE MANUFACTURE OF A MEDICAMENT USEFUL IN THE TREATMENT OF VENOUS INSUFFICIENCY AND VENOUS ULCERS
WO1997009329A1 (en) 1995-09-08 1997-03-13 J. Uriach & Cia. S.A. Azo derivatives of 5-aminosalicylic acid for treatment of inflammatory bowel disease
US6436969B1 (en) * 1995-09-12 2002-08-20 Kansas University Medical Center Research Institute Inc. Dialysis solutions and methods
IT1277663B1 (en) 1995-09-28 1997-11-11 Crinos Industria Farmaco STABLE AQUEOUS SUSPENSIONS OF MESALAZINE FOR TOPICAL USE
US6008208A (en) * 1995-10-23 1999-12-28 Osteoscreen, Inc. Compositions and methods for treating bone deficit conditions
AU7664296A (en) * 1995-11-02 1997-05-22 Warner-Lambert Company Naphthylazo inhibition of amyloidosis
US5747532A (en) 1995-11-21 1998-05-05 Medinox, Inc. Combinational therapeutic methods employing nitric oxide scavengers and compositions useful therefor
GB9602444D0 (en) * 1996-02-07 1996-04-03 Chege Joseph Pharmaceutical compositions for the prevention or treatment of retrovirus infections
US6355680B1 (en) * 1996-02-20 2002-03-12 Exocell, Inc. Albumin-binding compounds that prevent nonenzymatic glycation and that may be used for treatment of glycation-related pathologies
CA2248549A1 (en) * 1996-03-15 1997-09-18 Munin Corporation Extracellular matrix signalling molecules
CA2249299C (en) 1996-03-22 2004-02-17 Mayo Foundation For Medical Education And Research Combination of an ursodeoxycholic acid compound and a nsaid for the chemopreventive protection of the colorectum
DE19621840A1 (en) * 1996-05-31 1997-12-04 Basf Ag Process for the preparation of phenylazonaphthalenes
KR20000022040A (en) 1996-06-20 2000-04-25 보오드 오브 리젠츠, 더 유니버시티 오브 텍사스 시스템 Compounds and methods for providing pharmacologically active preparations and uses thereof
US5741896A (en) * 1996-06-21 1998-04-21 Allergan O- or S- substituted tetrahydronaphthalene derivatives having retinoid and/or retinoid antagonist-like biological activity
DE19627424A1 (en) 1996-07-08 1998-01-15 Bayer Ag Process for the preparation of 4-hydroxyanilines
US5935581A (en) * 1996-07-24 1999-08-10 Kapadia; Govind J. Inhibitory effects of synthetic and natural colorants on carcinogenesis
US5939456A (en) * 1996-07-26 1999-08-17 Perrine; Susan P. Pulsed administration of compositions for the treatment of blood disorders
US6245735B1 (en) 1996-07-29 2001-06-12 The Brigham And Women's Hospital, Inc. Methods and products for treating pseudomonas infection
US7030146B2 (en) * 1996-09-10 2006-04-18 University Of South Carolina Methods for treating diabetic neuropathy
US20030013746A1 (en) * 1996-09-10 2003-01-16 University Of Kansas Medical Center. Advanced glycation end-product intermediaries and post-amadori inhibition
CA2266404A1 (en) 1996-09-17 1998-03-26 Amur Pharmaceuticals, Inc. Phospholipid drug derivatives
KR100479314B1 (en) * 1996-10-11 2006-03-23 가부시키가이샤 우에노 세이야꾸 오요 겡뀨조 Naphthol derivative and process for preparing the same
US5840966A (en) 1996-10-17 1998-11-24 Minister Of Health And Welfare Hydroxylation of salicylic acid derivatives
US5939455A (en) * 1997-03-11 1999-08-17 Beacon Laboratories, Inc. Therapeutic augmentation of oxyalkylene diesters and butyric acid derivatives
SE9700934D0 (en) * 1997-03-14 1997-03-14 Astra Ab New formulation
US6551632B2 (en) * 1997-04-01 2003-04-22 Thomas Julius Borody Methods and compositions for treating inflammatory bowel disease
NZ500696A (en) 1997-04-01 2002-05-31 Borody Thomas J Methods and compositions for treating inflammatory bowel disease comprising mycobacterial agents, including macrolides
AUPO665397A0 (en) 1997-05-07 1997-05-29 Borody, Thomas Julius Novel therapy for constipation
US5962710A (en) 1997-05-09 1999-10-05 Emisphere Technologies, Inc. Method of preparing salicyloylamino acids
KR20010013377A (en) * 1997-06-04 2001-02-26 데이비드 엠 모이어 Mild, leave-on antimicrobial compositions
US6525038B1 (en) * 1997-06-24 2003-02-25 Werner Kreutz Synergistic compositions for the selective control of tumor tissue
DE19732903A1 (en) * 1997-07-30 1999-02-04 Falk Pharma Gmbh Pellet formulation for the treatment of the intestinal tract
US6486214B1 (en) 1997-09-10 2002-11-26 Rutgers, The State University Of New Jersey Polyanhydride linkers for production of drug polymers and drug polymer compositions produced thereby
US6281175B1 (en) 1997-09-23 2001-08-28 Scimed Life Systems, Inc. Medical emulsion for lubrication and delivery of drugs
FR2772375B1 (en) * 1997-12-15 2000-01-14 Atochem Elf Sa PROCESS FOR PACKAGING LONG CHAIN ALKYL ACRYLATES
US6660283B2 (en) 1997-12-19 2003-12-09 Societe L'oreal S.A. Use of cinnamic acid, or of at least one of its derivatives in a cosmetic composition
FR2772612B1 (en) 1997-12-19 2003-01-10 Oreal USE OF CINNAMIC ACID OR DERIVATIVES THEREOF IN A FIRMING COSMETIC COMPOSITION
WO1999040883A2 (en) * 1998-02-11 1999-08-19 Faller Douglas V Compositions and methods for the treatment of cystic fibrosis
AU4154799A (en) * 1998-06-02 1999-12-20 Arthromics Plc Compounds which interact with the thyroid hormone receptor for the treatment of fibrotic disease
US6258849B1 (en) * 1998-07-23 2001-07-10 Stanislaw R. Burzynski Treatment regimen for administration of phenylacetylglutamine, phenylacetylisoglutamine, and/or phenylacetate
KR20000011247A (en) 1998-07-23 2000-02-25 김윤 Composition and pharmaceutical dosage form for colonic drug delivery using polysaccharides
IT1303672B1 (en) 1998-07-28 2001-02-23 Nicox Sa NITRATED SALTS OF DRUGS ACTIVE IN BONE DISORDERS
FR2782269B1 (en) * 1998-08-17 2001-08-31 Oreal COSMETIC AND / OR DERMATOLOGICAL COMPOSITION CONTAINING SALICYLIC ACID OR A SALICYLIC ACID DERIVATIVE AND USE THEREOF
GB9818689D0 (en) * 1998-08-28 1998-10-21 Zeneca Ltd Compounds
CN1515547A (en) * 1998-10-16 2004-07-28 ��ʽ������Ұ��ҩӦ���о��� Naphthol derivative
IL126991A0 (en) 1998-11-10 1999-09-22 Yeda Res & Dev Azobenzene derivatives and intermediates thereof
ATE234090T1 (en) * 1998-11-13 2003-03-15 Lilly Co Eli COMBINATION OF DULOXETINE WITH NON-STEROID ANTI-INFLAMMATORY DRUGS FOR THE TREATMENT OF PAIN
DE19858997A1 (en) * 1998-12-21 2000-06-29 Dystar Textilfarben Gmbh & Co Thermal migration-compatible azo dyes
US6207700B1 (en) * 1999-01-07 2001-03-27 Vanderbilt University Amide derivatives for antiangiogenic and/or antitumorigenic use
US6326364B1 (en) * 1999-02-08 2001-12-04 Cedars-Sinai Medical Center Use of 5-aminosalicylates as antimicrobial agents
US6589944B1 (en) 1999-04-05 2003-07-08 City Of Hope Breakers of advanced glycation endproducts
US6383471B1 (en) 1999-04-06 2002-05-07 Lipocine, Inc. Compositions and methods for improved delivery of ionizable hydrophobic therapeutic agents
US6423696B1 (en) 1999-04-16 2002-07-23 The United States Of America, As Represented By The Department Of Health & Human Services Inhibition of arylamine N-acetyl transferase
DE50001030D1 (en) 1999-05-10 2003-02-13 Ciba Sc Holding Ag Azo dyes, processes for their preparation and their use for dyeing or printing natural or synthetic materials
US6200964B1 (en) * 1999-05-28 2001-03-13 Neutrogena Corporation Silicone gel containing salicylic acid
US6403646B1 (en) * 1999-06-30 2002-06-11 David H. Perlmutter Method for the treatment of alpha-1-antitrypsin deficiency and related pathologies
US6653352B2 (en) 1999-09-29 2003-11-25 Medical Merchandising, Inc. Pain reliever and method of use
US6531291B1 (en) * 1999-11-10 2003-03-11 The Trustees Of Columbia University In The City Of New York Antimicrobial activity of gemfibrozil and related compounds and derivatives and metabolites thereof
JP4168557B2 (en) 1999-11-25 2008-10-22 三浦工業株式会社 Hardness measuring indicator and hardness measuring method
ES2287040T3 (en) * 1999-12-06 2007-12-16 Leo Pharma A/S AMINOBENZOPENONES AS INHIBITORS OF IL-BETA AND TNF-ALFA.
CA2393083C (en) * 1999-12-23 2010-01-26 Novartis Ag Use of hypoglycemic agent for treating impaired glucose metabolism
AU2001241632A1 (en) * 2000-02-28 2001-09-12 The Procter And Gamble Company Acidic antimicrobial compositions for treating food and food contact surfaces and methods of use thereof
US6887632B2 (en) * 2000-03-30 2005-05-03 Council Of Scientific And Industrial Research Liquid crystalline polymer films of polymers having azobenzene mesogenic groups in cross linked network structures, process for the preparation thereof, polymers and novel monomers having azobenzene mesogens
US20020120008A1 (en) * 2000-06-29 2002-08-29 Seymour Benzer Life extension of drosophila by a drug treatment
DE10032019A1 (en) * 2000-07-01 2002-01-10 Clariant Gmbh Process for the preparation of disazo condensation pigments in microreactors
US6566507B2 (en) 2000-08-03 2003-05-20 Ciba Specialty Chemicals Corporation Processes for the preparation of benzotriazole UV absorbers
US6375733B1 (en) * 2000-08-28 2002-04-23 Engelhard Corporation Heat stable monoazo magenta pigment compositions
US6380256B1 (en) 2000-08-29 2002-04-30 Allergan Sales, Inc. Compounds having activity as inhibitors of cytochrome P450RAI
ATE460394T1 (en) 2000-08-29 2010-03-15 Biocon Ltd 5-ASA DERIVATIVES HAVING ANTI-INFLAMMATORY AND ANTIBIOTIC ACTION AND METHOD FOR TREATING DISEASES USING THESE DERIVATIVES
US6313107B1 (en) * 2000-08-29 2001-11-06 Allergan Sales, Inc. Methods of providing and using compounds having activity as inhibitors of cytochrome P450RAI
EP1642885B1 (en) * 2000-08-29 2009-11-11 Biocon Limited Use of a pharmaceutical composition containing a para-aminophenyl acetic acid derivative for treating inflammatory conditions of the gastrointestinal tract
US6369261B1 (en) 2000-08-29 2002-04-09 Allergan Sales, Inc. Compounds having activity as inhibitors of cytochrome P450RAI
US6387951B1 (en) * 2000-08-29 2002-05-14 Allergan Sales, Inc. Compounds having activity as inhibitors of cytochrome P450RAI
US6387952B1 (en) 2000-09-19 2002-05-14 Arco Chemical Technology L.P. Method of treating gastrointestinal disorders, particularly colitis
US20020061339A1 (en) * 2000-09-28 2002-05-23 Martin Stogniew Compositions and methods for use of extracts of rutaceae plants
MXPA03008108A (en) * 2001-03-07 2003-12-12 Procter & Gamble Topical composition comprising a functional aromatic derivative cosmetic bonding agent.
US7238680B2 (en) 2001-06-01 2007-07-03 Rosen Steven E Topical compositions for veterinary uses
US6791788B2 (en) * 2001-06-29 2004-09-14 Storage Technology Corporation Segmented power strip for an automated robotic device and method for joining same
US6528076B2 (en) * 2001-07-06 2003-03-04 Magic Herb Corp. Topical compositions and methods for treating pain
US6479528B1 (en) * 2001-07-31 2002-11-12 Neuronautics, Inc. Methods for inhibiting or reversing tau filament formation polymerization
US7022333B2 (en) * 2001-10-02 2006-04-04 Kimberly-Clark Worldwide, Inc. Inhibition of exoprotein production in non-absorbent articles uisng aromatic compositions
CA2464531A1 (en) * 2001-11-05 2003-05-15 Brigham And Women's Hospital, Inc. Soluble cd40l(cd154) as a prognostic marker of atherosclerotic diseases
EP1456165A1 (en) * 2001-11-30 2004-09-15 The Burnham Institute Induction of apoptosis in cancer cells
US6548776B1 (en) * 2002-04-12 2003-04-15 Jenn Feng Industrial Co., Ltd. Safety device for on/off switch of an electric tool

Also Published As

Publication number Publication date
TWI249519B (en) 2006-02-21
EP1642885A1 (en) 2006-04-05
US20050054728A1 (en) 2005-03-10
IL205420A (en) 2013-04-30
JP4163946B2 (en) 2008-10-08
WO2002018324A2 (en) 2002-03-07
DK1313697T3 (en) 2006-04-10
US20050228051A1 (en) 2005-10-13
EP1313697A2 (en) 2003-05-28
AU2001285311B2 (en) 2005-09-15
AU2005244526A1 (en) 2006-01-12
ES2254470T3 (en) 2006-06-16
IL205420A0 (en) 2011-07-31
ES2333337T3 (en) 2010-02-19
US20030191186A1 (en) 2003-10-09
DE60140491D1 (en) 2009-12-24
EP1642885B1 (en) 2009-11-11
WO2002018324A3 (en) 2002-08-29
AU8531101A (en) 2002-03-13
IL154536A (en) 2010-11-30
ATE448194T1 (en) 2009-11-15
AU2005244526B2 (en) 2009-09-10
EP1313697B1 (en) 2005-11-30
DE60115465D1 (en) 2006-01-05
PT1642885E (en) 2009-12-17
CY1110593T1 (en) 2015-04-29
CA2495537C (en) 2010-03-30
HK1089749A1 (en) 2006-12-08
MXPA03001787A (en) 2003-06-09
DE60115465T2 (en) 2006-08-03
CA2420576C (en) 2005-06-14
DK1642885T3 (en) 2010-01-04
HK1054221A1 (en) 2003-11-21
IL154536A0 (en) 2003-09-17
US7151095B2 (en) 2006-12-19
CA2495537A1 (en) 2002-03-07
US6583128B2 (en) 2003-06-24
US20070004800A1 (en) 2007-01-04
US7119119B2 (en) 2006-10-10
ATE311358T1 (en) 2005-12-15
JP2004517813A (en) 2004-06-17
US20020049186A1 (en) 2002-04-25
US7425578B2 (en) 2008-09-16
US6903082B2 (en) 2005-06-07

Similar Documents

Publication Publication Date Title
CA2420576A1 (en) Immunoregulatory compounds, derivatives thereof and their use
NO20074657L (en) Nitrogen-containing aromatic ring compounds
NO2015020I2 (en) Ceritinib or a pharmaceutically acceptable salt thereof
IL143978A0 (en) Colchinol derivatives as vascular damaging agents
IL154537A0 (en) 5-asa derivatives having anti-inflammatory and antibiotic activity and methods of treating diseases therewith
WO2002100833A1 (en) Rho KINASE INHIBITORS
EP1165490A4 (en) Substituted 2-aminobenzamide caspase inhibitors and the use thereof
YU77101A (en) Renin inhibitors
CA2380414A1 (en) Method of cancer treatment
WO2003082861A3 (en) Morpholinyl-urea derivatives for use of the treatment of inflammatory diseases
WO2004080408A3 (en) Method of treating cancer with azaspirane compositions
TWI256314B (en) Preventive-therapeutical medicament for gastroesophageal reflux disease
CA2362211A1 (en) Benzamide derivatives and medicament containing the same
NZ332687A (en) use of 1-methyl-carbapenem derivatives as anti-helicobacter pylori agents
AU2406700A (en) 3,4-dihydro-2h-benzo(1,4)oxazinyl-methyl(3-(1h-indol-3-yl)-a kyl)-amines
TW200407315A (en) Pyrimidine derivatives
HK1075656A1 (en) New piperidinyl-alkylamino-pyridazinone derivatives, a process for the preparation thereof and pharmaceutical compositions containing said compounds
CA2192596A1 (en) 4-(6-fluoro-1,2-benzisoxazolyl)-1-piperidinyl-propoxy-chromen-4-one derivatives, their preparation and their use in the treatment of psychosis, schizophrenia and anxiety
GB1565767A (en) Substituted 1,2,4 - triazines processes for their preparation and pharmaceutical compositions containing them
EP1333024A4 (en) Peptide derivatives and their pharmaceutically acceptable salts, processes for preparation of both, and use thereof
EA200600270A1 (en) APPLICATION OF 2H- [1,3] -OXASINO [3,2-A] INDOL DERIVATIVES FOR THE TREATMENT OF NEUROPATHIC PAIN
KR950032200A (en) Imidazopyridine derivatives and preparation method thereof
TW353071B (en) Chromene compounds with neutroleptic activity, their preparation and pharmaceutical compositions
MX2008002753A (en) Pyridazinone derivatives used for the treatment of pain.
TH83055B (en) Piperacinyl acylpiperidine derivatives, such preparations and therapeutic uses.

Legal Events

Date Code Title Description
EEER Examination request
MKEX Expiry

Effective date: 20210830